Key facts
- This page summarizes Semigran Marc's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Dec 2024, 16:30.
Semigran Marc - 24 Dec 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- EWTX
- Reported as of
- 24 Dec 2024
- Net transaction value
- -$616,317
- SEC form
- 4
- Accepted by SEC
- 27 Dec 2024, 16:30:04 UTC
- Prior SEC filing
- 14 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John R. Moore, Attorney-in-Fact for Semigran Marc
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Semigran Marc filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 27 Dec 2024.
Change
- Previous filing in this sequence was filed on 14 Aug 2024.
- Current net transaction value: -$616,317.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EWTX
transaction
Common Stock
Options Exercise
- Transaction value
- $265,598
- Shares
- +29,709
- Change %
- +442%
- Price
- $8.94
- Shares after
- 36,425
- Date
- 24 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
EWTX
transaction
Common Stock
Sale
- Transaction value
- $829,906
- Shares
- -27,980
- Change %
- -77%
- Price
- $29.66
- Shares after
- 8,445
- Date
- 24 Dec 2024
- Ownership
- Direct
- Footnotes
- F2, F3
EWTX
transaction
Common Stock
Sale
- Transaction value
- $52,009
- Shares
- -1,729
- Change %
- -20%
- Price
- $30.08
- Shares after
- 6,716
- Date
- 24 Dec 2024
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EWTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -29,709
- Change %
- -9.9%
- Price
- $0.000000
- Shares after
- 270,291
- Date
- 24 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,709
- Exercise price
- $8.94
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024.
Footnote F3
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.